与克拉维酸、他唑巴坦和舒巴坦联合使用相比，13种β-内酰胺类药物与BRL 42715联合使用对产β-内酰胺酶革兰氏阴性菌的活性。

Activity of 13 beta-lactam agents combined with BRL 42715 against beta-lactamase producing gram-negative bacteria compared to combinations with clavulanic acid, tazobactam and sulbactam.

作者信息

Piddock L J, Jin Y F, Turner H L

机构信息

Department of Infection, University of Birmingham, UK.

出版信息

J Antimicrob Chemother. 1993 Jan;31(1):89-103. doi: 10.1093/jac/31.1.89.

DOI:10.1093/jac/31.1.89

Abstract

The activity of six cephalosporins, six penicillins and one monobactam combined with BRL 42715, clavulanic acid, sulbactam or tazobactam at 0.1, 0.5, 1, 2, 5 and 10 mg/L was determined for 45 beta-lactamase producing Gram-negative bacteria. The combination of BRL 42715 with any of the agents was more active than any of the other inhibitor and beta-lactam combinations. Unlike the other beta-lactamase inhibitors, BRL 42715 enhanced the activity of the beta-lactams for strains that constitutively expressed Richmond & Sykes Class I beta-lactamase and against strains expressing extended-spectrum plasmid-mediated beta-lactamases.

摘要

针对45株产β-内酰胺酶的革兰氏阴性菌，测定了六种头孢菌素、六种青霉素和一种单环β-内酰胺与浓度为0.1、0.5、1、2、5和10mg/L的BRL 42715、克拉维酸、舒巴坦或他唑巴坦联合使用时的活性。BRL 42715与任何一种药物联合使用时，其活性均高于其他任何抑制剂与β-内酰胺的组合。与其他β-内酰胺酶抑制剂不同，BRL 42715可增强β-内酰胺对组成型表达里士满&赛克斯I类β-内酰胺酶菌株以及对表达超广谱质粒介导β-内酰胺酶菌株的活性。

相似文献

1

Activity of 13 beta-lactam agents combined with BRL 42715 against beta-lactamase producing gram-negative bacteria compared to combinations with clavulanic acid, tazobactam and sulbactam.

J Antimicrob Chemother. 1993 Jan;31(1):89-103. doi: 10.1093/jac/31.1.89.

2

Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam.

Braz J Infect Dis. 2000 Feb;4(1):22-8.

3

Susceptibility of clinical isolates to expanded-spectrum beta-lactams alone and in the presence of beta-lactamase inhibitors.

Chemotherapy. 1996 Sep-Oct;42(5):334-42. doi: 10.1159/000239464.

4

In-vitro evaluation of the four beta-lactamase inhibitors: BRL42715, clavulanic acid, sulbactam, and tazobactam.

J Antimicrob Chemother. 1993 Sep;32(3):421-9. doi: 10.1093/jac/32.3.421.

5

Evolution of beta-lactamase inhibitors.

Rev Infect Dis. 1991 Jul-Aug;13 Suppl 9:S727-32. doi: 10.1093/clinids/13.supplement_9.s727.

6

Tazobactam-piperacillin compared with sulbactam-ampicillin, clavulanic acid-ticarcillin, sulbactam-cefoperazone, and piperacillin for activity against beta-lactamase-producing bacteria isolated from patients with complicated urinary tract infections.

J Chemother. 1997 Apr;9(2):89-94. doi: 10.1179/joc.1997.9.2.89.

7

Penetration of beta-lactamase inhibitors into the periplasm of gram-negative bacteria.

FEMS Microbiol Lett. 1999 Jul 1;176(1):11-5. doi: 10.1111/j.1574-6968.1999.tb13635.x.

8

Comparative in vitro and in vivo activities of piperacillin combined with the beta-lactamase inhibitors tazobactam, clavulanic acid, and sulbactam.

Antimicrob Agents Chemother. 1989 Nov;33(11):1964-9. doi: 10.1128/AAC.33.11.1964.

9

Antimicrobial susceptibilities of Campylobacter jejuni and Campylobacter coli to 12 beta-lactam agents and combinations with beta-lactamase inhibitors.

Antimicrob Agents Chemother. 1996 Aug;40(8):1924-5. doi: 10.1128/AAC.40.8.1924.

10

In vitro activities of the beta-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with beta-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strains.

Antimicrob Agents Chemother. 2004 May;48(5):1586-92. doi: 10.1128/AAC.48.5.1586-1592.2004.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。